Intuitive Surgical (NASDAQ:ISRG) hit a major financial landmark Wednesday, reporting preliminary 2025 revenue of $10.06 billion, a 21% increase over the prior year.
The results, fueled by the rapid rollout of the next-generation da Vinci 5 system, underscore the company’s dominant grip on the robotic-assisted surgery market as it transitions from a niche technology provider to a foundational healthcare infrastructure giant.
For the fourth quarter ended December 31, 2025, revenue reached $2.87 billion, a 19% year-over-year jump.
The primary engine of this growth was the high-margin "Instruments & Accessories" segment, which generated $1.66 billion in the quarter—nearly 58% of total revenue—as surgeons performed a record 3.15 million procedures globally throughout the year.
The 2025 results reveal a massive shift in Intuitive’s capital equipment portfolio.
Of the 1,721 systems placed during the year, 870 (51%) were the new da Vinci 5 platform, which received broad FDA clearance and initial international regulatory nods earlier in 2024 and 2025.
In the fourth quarter alone, 303 of the 532 systems placed were da Vinci 5 units, indicating that hospitals are aggressively upgrading their fleets to access the system’s enhanced force-sensing capabilities and AI-driven data analytics.